GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (OTCPK:REGMF) » Definitions » LT-Debt-to-Total-Asset

REGMF (RemeGen Co) LT-Debt-to-Total-Asset : 0.24 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. RemeGen Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.24.

RemeGen Co's long-term debt to total assets ratio increased from Jun. 2023 (0.11) to Jun. 2024 (0.24). It may suggest that RemeGen Co is progressively becoming more dependent on debt to grow their business.


RemeGen Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for RemeGen Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co LT-Debt-to-Total-Asset Chart

RemeGen Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.01 0.01 0.02 0.17 0.23

RemeGen Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.11 0.17 0.24 0.23

RemeGen Co LT-Debt-to-Total-Asset Calculation

RemeGen Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=128.185/774.242
=0.17

RemeGen Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=193.283/793.215
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RemeGen Co  (OTCPK:REGMF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


RemeGen Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of RemeGen Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


RemeGen Co Business Description

Traded in Other Exchanges
Address
58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.